CLINICAL_TRIALS ClinicalTrials.gov record update

Multicentre, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab in Patients Suffering From Follicular Non-Hodgkin's Lymphoma (FNHL) With Residual Minimal Disease After Autologous Transplantation of hematopoïetic Stem Cell (Bone Marrow or Peripheral Blood)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01388959
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:23.569958+00:00
Published At: 2016-11-02T00:00:00+00:00
Record Updated At: 2016-11-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Hodgkin\u0027s Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-11-02"
protocolSection.identificationModule.nctId: "NCT01388959"
protocolSection.identificationModule.officialTitle: "Multicentre, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab in Patients Suffering From Follicular Non-Hodgkin\u0027s Lymphoma (FNHL) With Residual Minimal Disease After Autologous Transplantation of hematopo\u00efetic Stem Cell (Bone Marrow or Peripheral Blood)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.